TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06963827: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate Efficacy and Safety of Mezagitamab (TAK-079) in Study Participants With Primary IgA Nephropathy in Combination With Stable Background

Sponsor: Takeda · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 347 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$565,728

Rescue Site Savings

+$377,152

Unlock Full NCT06963827 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06963827 Rescue Dossier →